MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical and preclinical pipeline.
Stocks · News reference
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84
Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MBX Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate
Microbix Biosystems Inc. to Present at EMMD 2026
Microbix Biosystems Inc. is attending and presenting a scientific poster at the Experts in Molecular Diagnostics (EMMD) conference.
Microbix Biosystems Presents on Synthetic DNA and RNA Quality Assessment Products
Microbix Biosystems Inc. announced a presentation regarding its portfolio of synthetic DNA and RNA quality assessment products (QAPs) used as test controls.
Microbix Biosystems Inc. Reviews Impact of New U.S. Tariffs on Diagnostic Reagents
Microbix is assessing the potential impact of new 50% U.S. tariffs on Canadian diagnostic and laboratory reagents, which are scheduled to take effect on October 30, 2026.
Microbix Biosystems Inc. to Participate in Planet MicroCap Toronto 2026
Microbix Biosystems Inc. announced its participation in the upcoming Planet MicroCap Toronto 2026 conference.